SNDX - Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference
PR Newswire
WALTHAM, Mass. , Nov. 21, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at the Evercore ISI Annual HealthCONx Conference on Wednesday, November 30, 2022 , at 3:30 p.m. ET .
A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib (SNDX-5613), a highly selective inhibitor of the Menin–MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
SOURCE Syndax Pharmaceuticals, Inc.
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.